L. Hofbauer
Oncology · 2001–2017
A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 28 citations into it; #1,301 of 1,698 by trust here, #1,421 by citations
- Molecular Biology — 24 citations into it; #14,853 of 17,773 by trust here, #12,227 by citations
Whom L. Hofbauer trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts L. Hofbauer overall
Papers from L. Hofbauer's perspective
Ordered by how strongly the researchers L. Hofbauer trusts endorse each paper. Same corpus, a different order for every researcher.
- RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. (Proceedings of the National Academy of Sciences of the United States of America)
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption (Journal of Bone and Mineral Research)
- The osteoblast: a sophisticated fibroblast under central surveillance. (Science)
- Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts* (Journal of Biological Chemistry)
- Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis (Journal of Experimental Medicine)
- Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. (Journal of Clinical Investigation)
- Bone resorption by osteoclasts. (Science)
- Genetic regulation of osteoclast development and function (Nature reviews genetics)
- T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ (Nature)
- IL-1 mediates TNF-induced osteoclastogenesis. (Journal of Clinical Investigation)
Their papers
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (2016) — 1,423 citations
- Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. (2004) — 1,014 citations
- Osteoporosis treatment: recent developments and ongoing challenges (2017) — 839 citations
- New Horizons in Osteoporosis (2011) — 2,368 citations
- Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology (2001) — 624 citations